drugset / Trial / NCT06919666
NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Phase 1/2
Active not recruiting
29 enrolled
University of Colorado, Denver
Purple Biotech Ltd. · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
Fixed dose NT219 weekly plus pembrolizumab every 3 weeks or cetuximab weekly to be continued until progression, unacceptable toxicity, or investigator or participant decision.
Timeline
- Start
- 2025-06-12
- Primary completion
- 2030-02-01
- Completion
- 2031-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NT219 | Small molecule | 75 mg/kg | Intravenous |